Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
AVDL Stock Chart & Stats
$18.59
-$0.16(-1.47%)
At close: 4:00 PM EST
$18.59
-$0.16(-1.47%)
Day’s Range― - ―
52-Week Range$6.38 - $18.65
Previous CloseN/A
Volume358.54K
Average Volume (3M)3.34M
Market Cap
$1.81B
Enterprise Value$833.42M
Total Cash (Recent Filing)$81.55M
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 05, 2025EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding97,258,064
10 Day Avg. Volume7,442,670
30 Day Avg. Volume3,342,178
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue3.77
Enterprise Value/Gross Profit4.21
Enterprise Value/Ebitda125.48
Forecast
1Y Price Target
$19.13Price Target Upside2.90% Upside
Rating ConsensusHold
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsThe acquisition is intended to immediately advance Alkermes into the sleep space by bringing in Avadel’s commercial product LUMRYZ, and leveraging Avadel’s commercial infrastructure and experience in the sleep business.
Increased Sales ProjectionsLumryz is guided to reach $265-275M in 2025, and analysts think $550M+ peak sales could be conservative.
Successful Clinical TrialsThe phase 3 REVITALYZ trial evaluating Lumryz in IH is expected to readout topline data, with submission of an sNDA for IH, and is relatively derisked by the positive clinical data of Xywav in IH.
Bears Say
Competitive ConcernsThe purchase price for Avadel is considered attractive for Alkermes but likely reflects long-term competitive landscape concerns with respect to the oxybate class in sleep disorders.
Potential Generic CompetitionThe looming advent of sodium oxybate generics next year may also pressure pricing in the oxybate class.
Regulatory And Market RisksKey risks include changes in regulatory environment, market downturns and potential risks to completion of acquisition.
Avadel Pharmaceuticals News
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $6.38 and its highest was $18.65 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Avadel Pharmaceuticals’s market cap is $1.81B.
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 7 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.069.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is 0.06.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 97,258,064 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 14.775%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Currently, no hedge funds are holding shares in AVDL
Avadel Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.13 (2.90% Upside)
$19.13 (2.90% Upside)
Blogger Sentiment
Bullish
AVDL Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 692.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.8%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.09%
12-Months-Change
Fundamentals
Return on Equity
-3.63%
Trailing 12-Months
Asset Growth
18.81%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
AVDL Company Deck
AVDL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant growth in patient demand, strong financial performance, and successful litigation outcomes. Although there are some concerns regarding pending royalty determinations and increased operating expenses, the positive aspects significantly outweigh the lowlights, indicating a strong position for future growth.View all AVDL earnings summariesAVDL Stock 12 Month Forecast
Average Price Target
$19.13
▲(2.90% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Harrow Health
―
Ownership Overview
1.07% Insiders
12.63% Mutual Funds
0.17% Other Institutional Investors
74.81% Public Companies and
Individual Investors